Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017

LOS ANGELES (November 29, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s president, Andrew Ritter, will present at the 10th Annual LD Micro Conference on Tuesday, December 5, 2017, at […]

Leave Your Comments »

Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress

LOS ANGELES (November 2, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, will present at the 5th Microbiome R&D Business Collaboration Forum / 2nd […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES (October 31, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with an initial focus on developing the first FDA approved treatment for lactose intolerance, today reported financial results and a business update for […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering

Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with an initial focus on developing the first FDA approved treatment for lactose intolerance, today announced the pricing of […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance

Los Angeles, California, October 3, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering with total gross proceeds to the Company of approximately $23 […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance

Company has incorporated guidance from FDA on key elements of its Phase 3 program to support a New Drug Application (NDA) for RP-G28 Los Angeles, California, August 18, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced its […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

LOS ANGELES (August 7, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the second quarter ended June 30, 2017. Recent Highlights Announced that the FDA has agreed to schedule […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms

Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments Los Angeles, California, August 3, 2017 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases today announced additional findings and data analysis from its Phase 2b/3 study designed to evaluate […]

Leave Your Comments »

Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates

LOS ANGELES (May 9, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the first quarter ended March 31, 2017 and provided other business updates. Recent Highlights Clinical microbiome data […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3

LOS ANGELES (May 2, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has been issued three new patents directed to its development compound RP-G28.  The Company is also providing an […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD